Mergers, Acquisitions Leading? ‘Exit Strategy’ For Biotech Companies

Investors and biotech companies say mergers and acquisitions continue to be a better exit strategy than initial public offerings.Investors trying to get the most out of their buck as the industry matures say an IPO isn’t always the best route.